国际标准期刊号: 2469-9764

工业化学:开放获取

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 参考搜索
  • 研究期刊索引目录 (DRJI)
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 学者指导
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
分享此页面

抽象的

Development of Combined Transdermal Patch Formulations Incorporating Salbutamol Sulfate and Ketotifen Fumarate for Respiratory Conditions

Mustafa Soylak

Salbutamol sulfate and ketotifen fumarate are widely used medications for the treatment of respiratory conditions, such as asthma and allergic rhinitis. In this study, we aimed to develop a novel combined transdermal patch formulation containing both salbutamol sulfate and ketotifen fumarate. The transdermal patch offers several advantages over conventional oral dosage forms, including improved patient compliance, sustained drug release, and reduced systemic side effects. The formulations were prepared using a blend of polymers, permeation enhancers, and drug-loaded reservoirs. Physicochemical characterization, in vitro drug release studies, and skin permeation studies were conducted to evaluate the performance of the transdermal patches. Furthermore, the stability of the formulations was assessed over a predetermined period. The results demonstrated that the developed transdermal patches exhibited sustained drug release profiles of both salbutamol sulfate and ketotifen fumarate, and demonstrated satisfactory permeation through the skin. The stability studies revealed that the formulations maintained their integrity and drug content throughout the storage period. These findings suggest that the developed combined transdermal patch formulation has the potential to provide a convenient and effective treatment option for respiratory conditions.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。